Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study

AbstractIntroductionOptimal dual antiplatelet therapy (DAPT) duration for medically managed acute coronary syndrome (ACS) (MMACS) patients is still unknown. We explored the efficacy and safety of  ≥ 12-month DAPT among MMACS patients.MethodsIn this sub-analysis of the optimal antiplatelet therapy for Chinese Patients with Coronary Artery Disease study (NCT01735305), clinical outcomes among MMACS patients were compared between the  
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research

Related Links:

More News: Academia | Angioplasty | Bleeding | China Health | Coronary Angioplasty | Drugs & Pharmacology | Heart Attack | Ischemic Stroke | Percutaneous Coronary Intervention | Stroke | Study